Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE, OTC:GNTLF) CEO Simon Morriss tells Proactive the focus over the next 18 months is putting the pathway in place to see the business on track to profitability. GTG recently confirmed that its expanded geneType Multi-Risk Test, to include three new diseases - pancreatic cancer, melanoma and atrial fibrillation - is now available to order in Australia, following the launch of the expanded test in the US in March. The geneType Multi-Risk Test now performs a total of nine individual serious disease risk assessments, all from the one simple saliva sample and caters for people of most ethnicities over the age of 30.
Genetic Technologies building pathway to profitability
